A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer

Tetsuo Shimizu,Yoshiko Nakagawa,Yasuo Asai,Ichirou Tsujino,Noriaki Takahashi,Yasuhiro Gon

A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer

2019

Tetsuo Shimizu
Yoshiko Nakagawa
Yasuo Asai
Ichirou Tsujino
Noriaki Takahashi
Yasuhiro Gon

ObjectiveThe standard therapies for previously treated advanced non-small cell lung cancer (NSCLC) include docetaxel (DOC). Bevacizumab (BV), an antivascular endothelial growth factor (VEGF) antibo...

Keywords:

Anesthesia
Bevacizumab
Cell
Diabetes mellitus
Phases of clinical research
Internal medicine
Medicine
Docetaxel
Oncology
Lung cancer
Growth factor
Chemotherapy
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations